PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biotechnology company focused on cell therapy for chronic kidney disease, primarily through its lead candidate REACT (Renal Autologous Cell Therapy). The company entered the public markets via a SPAC structure: blank-check company SCS Capital Acquisition Corp., sponsored by SCS Capital Management LLC, completed its IPO in 2021 and subsequently merged with ProKidney LLC. The de-SPAC transaction closed in January 2023, with the combined company listing on Nasdaq under the PROK ticker. The company operates in the healthcare and clinical-stage biopharmaceutical sector, with its therapeutic focus on slowing the progression of diabetic chronic kidney disease. For full filing history, pipeline details, and SPAC transaction data on ProKidney Corp. and hundreds of other deals, sign up for complete access at SpacDesk.